Journal
BIOANALYSIS
Volume 9, Issue 12, Pages 937-946Publisher
FUTURE SCI LTD
DOI: 10.4155/bio-2017-0024
Keywords
biomarker; immunoassay; ligand-binding assay; parallelism; platform comparison; ultrasensitive
Ask authors/readers for more resources
Aim: We evaluated three immunoassay-based technologies and their biomarker kits, by determining precision, parallelism and detectability of analytes of interest. Materials & methods: We compared ultrasensitive assays for three biomarkers: interleukins IL-6, IL-13 and IL-17A using kits obtained from Roche (IMPACT platform - proprietary platform), Singulex (Erenna (R)) and Quanterix (Simoa(TM)). We defined the true LLOD as the LLOQs, and provided disease-specific parallelism results and detectability levels for endogenous analyte, which were good across platforms, though they varied from analyte to analyte. Conclusion: We highlight a simplified approach employed for evaluating ultrasensitive kits and provide an overview of the methodologies used to compare available assays. All three platforms are able to detect very low-level analytes. We recommend all three platforms for detection of very low-level analytes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available